Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

References

• Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights in Europe (AIRE) study. Eur Respir J 2000;16:802–7
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein JJ, Rovers MM. Compliance with inhaled medication and self-treatment guidelines following a self-management programme in adult asthmatics. Eur Respir J 1997;10:652–7
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Washington (DC): National Institutes of Health, National Heart, Lung, and Blood Institute; 2002 [publication No. 02–3659]
   Google Scholar
• Ställberg B, Olsson T, Jörgensen LA, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003;57:656–61
   Google Scholar
• FitzGerald JM, Sears MR, Boulet LP, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003;10:427–34
   PubMedGoogle Scholar
• Aalbers R, Backer V, Kava TTK, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004;20:225–40
   PubMed Web of Science ®Google Scholar
• Haughney J, Barnes G, Partridge M. Living and breathing – a national survey of patients’ views of asthma and its treatment. Thorax 2001;56(Suppl. III):S51
   Google Scholar
• National Asthma Campaign. Out in the open. A true picture of asthma in the United Kingdom today. Asthma J 2001;6(Suppl.):1–16
   Google Scholar
• van der Palen J, Klein JJ, van Herwaarden CLA, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034–7
   PubMed Web of Science ®Google Scholar
• Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler^®. Respir Med 1998;92:1017–21
   Google Scholar
• Seberová E, Andersson A. Oxis (formoterol given by Turbu-haler^®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000;94:607–11
   Google Scholar
• Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003;97:1067–74
   PubMed Web of Science ®Google Scholar
• Rubinfeld, A, Scicchitano R, Hunt A, et al. Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma. Eur Respir J 2002;20\(Suppl. 38):52s [abstract No. P437]
   Google Scholar
• Balanag VM, Yunus F, Yang P-C, Jorup C. Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents. Eur Respir J 2003;22\(Suppl. 45):445s [abstract No. P2836]
   Google Scholar
• Pauwels RA, Campbell M, Villasante C, et al. Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: outcomes from the RELIEF study in patients across different severities and age groups. Eur Respir J 2003;22:787–94
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Ställberg B, et al. Single inhaler therapy with budesonide/formoterol provides superior asthma control compared with fixed dosing with budesonide plus terbutaline as needed. J Allergy Clin Immunol 2004;113\(Suppl. 2):S116 [abstract No. 360]
   Google Scholar
• American Thoracic Society (ATS). Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225–44
   Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party: standardization of lung function tests. European Community for Steel and Coal. Eur Respir J 1993;6 (Suppl. 16):5–40
   Google Scholar
• Hsu F-F, Wang L, Bier D. Determination of cortisol in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. Anal Biochem 1994;216:401–5
   Google Scholar
• Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405–11
   PubMed Web of Science ®Google Scholar
• Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000;320:1368–73
   Google Scholar
• Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363:271–5
   PubMed Web of Science ®Google Scholar
• Gibson PG, Wong BJ, Hepperle MJ, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992;22:525–32
   PubMed Web of Science ®Google Scholar
• Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999;160:594–9
   PubMed Web of Science ®Google Scholar
• Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982;70: 288–98
   Google Scholar
• Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117:440–6
   Google Scholar
• Tattersfield AE, Löfdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001;357:257–61
   PubMed Web of Science ®Google Scholar
• van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004;17:89–95
   PubMed Web of Science ®Google Scholar
• Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457–63
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2484–9
   Google Scholar
• Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003;16:147–51
   Google Scholar
• Jenkins C, Kolarikova R, Kuna P, et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma. Am J Respir Crit Care Med 2003;167:A892
   Google Scholar